OLMA
Olema Oncology, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 3 to Mar 4 ▼ 2 days of insider sells: $951.5K by 1 insider, avg $23.79
- May 21 ▲ Olema Pharmaceuticals announced preliminary Phase 1 data for OP-3136…
- May 21 ▲ Olema Oncology announced preliminary Phase 1 data for OP-3136, a KAT…
- May 21 FDA: Olema Oncology Announces Encouraging Initial Clinical Data…
- May 26 ▲ Olema Pharmaceuticals announced a clinical trial collaboration and s…
- May 26 FDA: Olema Oncology Announces Clinical Trial Collaboration and…
- Jul 23 to Jul 24 ▼ 2 days of insider sells: $291.2K by 1 insider, avg $11.65
- Aug 9 ▼ Institutional cluster for OLMA shows net selling of ~$27.4M in Q2 20…
- Oct 2 Activist stake: Olema Oncology Reports Inducement Grants Under Nasdaq List…
- Nov 10 ▼ Earnings: OLMA Q3 2026 Earnings: EPS $-0.73 (-14.5% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $1.2M.
- InstitutionsBULLISH
Q3 2026: 23 added (0 new), 12 trimmed or exited.
- AnalystsBULLISH
16 of 18 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.579 → −$0.634 over 90 days. 1 up, 7 down in 30 days.
- Short sellersSTEADY
Short interest +9.2% to 17.12M shares. 11.9 days to cover, ≈19.6% of shares.
- TrendRANGE
9% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $20.6M |
| Candriam S.C.A. | ADD | $10.3M |
| UBS Group AG | ADD | $2.6M |
| Squarepoint Ops LLC | TRIM | $1.7M |
| ALPS ADVISORS INC | ADD | $1.0M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | $917.6K |
| Creative Planning | ADD | $830.7K |
| Quantinno Capital Management LP | ADD | $674.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is below the lowest target. Median implies +382%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 14, 2026 | Stifel MAINTAIN | Buy |
| Aug 13, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 11, 2026 | Citigroup MAINTAIN | Buy |
| Aug 11, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
O'Byrne Jason CHIEF FINANCIAL OFFICER Sep 1, 2026 | AWARD | 650,000 sh |
Harmon Cyrus Director Jul 24, 2026 | SELL | $146.4K |
Harmon Cyrus Director Jul 23, 2026 | SELL | $144.7K |
Graham G. Walmsley Director Jun 18, 2026 | AWARD | 29,500 sh |
RAPPAPORT ANDREW Director Jun 18, 2026 | AWARD | 29,500 sh |
Raman Prakash Director Jun 18, 2026 | AWARD | 29,500 sh |
Horning Sandra Director Jun 18, 2026 | AWARD | 29,500 sh |
Larson Yi Director Jun 18, 2026 | AWARD | 29,500 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.63 | -$0.73–-$0.50 | +0.0% | $0.00 |
| Next Q | -$0.70 | -$0.81–-$0.63 | -16.0% | $0.00 |
| Current FY | -$2.56 | -$3.13–-$2.14 | -7.6% | $0.00 |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 6 press releases · 2 bullish · 1 bearish · 11 neutral- NEUTRAL SC 13G/ANov 16, 2026
Janus Henderson Group Ltd. filed an amended Schedule 13G disclosing beneficial ownership of 6,318,050 shares of Olema Oncology (OLMA) common stock, representing 7.2% of shares outstanding as of September 30, 2026. This is a passive investment disclosure; the filing does not provide a comparison to…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 12, 2026
Olema Pharmaceuticals, Inc. changed its corporate name to Olema Oncology, Inc. via an Eighth…
The name change and office relocation are routine corporate actions with no expected impact on operations or stock performance. Monitor for any future business development announcements under the…
- NEUTRAL PRESS-RELEASENov 10, 2026
Olema Oncology reported Q3 2026 net loss of $73.6M ($0.73 per share) vs. consensus $-0.63, with no…
The key catalyst is the OPERA-01 top-line data in Q1 2027. Monitor enrollment updates for OPERA-02 and any early efficacy signals from the upcoming SABCS presentations in December 2026.
- NEUTRAL INST-CLUSTERNov 6, 2026
Five asset managers added to their OLMA positions in Q3 2026, led by Candriam S.C.A. increasing…
The cluster is dominated by asset managers, not activist or event-driven funds, and the 45-day lag means positions may have changed. Watch for any insider Form 4 filings or a catalyst (e.g., trial…
All OLMA filing & press-release reports (20)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 12, 2026
- PRESS-RELEASE reportNov 10, 2026
- INST-CLUSTER reportNov 6, 2026
- SC 13D/A reportOct 16, 2026
- 8-K reportOct 15, 2026
- PRESS-RELEASE reportOct 2, 2026
- 8-K reportAug 10, 2026
- PRESS-RELEASE reportAug 10, 2026
- INST-CLUSTER reportAug 9, 2026
- 8-K reportMay 26, 2026
- PRESS-RELEASE reportMay 26, 2026
- 8-K reportMay 21, 2026
- PRESS-RELEASE reportMay 21, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- DEFA14A reportApr 29, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportMar 16, 2026